Inventiva S.A. (IVEVF)
- Globe Newswire
Inventiva reports 2022 First Quarter Financial Information and provides clinical development update
Cash position2 at €80.5m as of March 31, 2022The Group did not generate any revenue in Q1 2022Signature of a €50 million bullet credit facility agreement with the European Investment BankUpdate on lanifibranor recruitment timing for Phase III trial in patients with NASH, as well as for the two Phase II trials in patients with NAFLD and type 2 diabetes, and in combination with empagliflozine Daix (France), Long Island City (New York, United States), May 16, 2022 – Inventiva (Euronext Paris and Na
- Globe Newswire
Inventiva secures a €50 million credit facility from the European Investment Bank
This credit facility is intended to support the progress and expansion of Inventiva’s pipelineThe credit facility consists of two tranches of €25 million eachCredit agreement is part of the European Investment Bank’s strategy to support biotech companies developing a high-level of expertise in various therapeutic areas with significant unmet medical needs Daix (France), Long Island City (New York, United States), May 16, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinic
- Globe Newswire
Statement of total voting rights and shares forming the company’s share capital as of April 11, 2022
Article R. 22-10-23 of the French Commercial Code Market : Euronext ParisISIN code / Mnemo : FR0013233012 / IVAWeb site : www.inventivapharma.com DateNumber of Shares Outstanding Total voting rights, gross (1) Total voting rights, net (2)April 11, 202240 873 55152 801 40952 741 093 The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the b
